Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study
Altimmune reports positive Phase 2 RECLAIM trial data for pemvidutide in AUD and plans to request an EOP2 meeting with the FDA.
Altimmune's medicine for alcohol use disorder (when people struggle to cut back on drinking) worked better than expected in mid-stage testing. When a company shows good test results, people often watch to see if the medicine can help patients safely before deciding what the company is really worth.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.